Abstract
Contact X-ray therapy (CXRT) with a 50 kV beam was first designed in Germany in 1933 (Siemens company). Between 1960 and 1990, Papillon in France popularized this technique for rectal cancer using a Philips RT50 device. Since then, CXRT has been used in Europe and North America. It was the first technique that was able to cure adenocarcinoma of the rectum, which till the 1970s was considered a radioresistant tumor, with radiotherapy alone. CXRT is a unique approach for rectal cancer because it allows very high doses of radiation to be accurately delivered to the tumor under direct visualization. CXRT alone can control the disease in 90% of cases of T1 N0 rectal adenocarcinoma with doses of 90–100 Gy delivered in three or four fractions over 4–5 weeks. Similarly, CXRT can be used after local excision for pT1 disease to increase tumor bed local control (45–50 Gy in three fractions in 3–4 weeks). CXRT with external beam radiotherapy (EBRT) can also be used with curative intent in inoperable elderly patients to treat T2–3 tumors measuring <5 cm in diameter, with local control achievable in 80% of T2 and 50% of T3 tumors. The Lyon R96.02 randomized trial has demonstrated that for T2 and small T3 tumors of the distal rectum, dose escalation (90 Gy/three fractions) with CXRT, in addition to preoperative EBRT, was able to increase the rate of sphincter preserving surgery (44–73%) and was compatible with transanal local excision (TLE) in patients achieving excellent response. A new CXRT machine,Papillon 50®, has been designed and will be commercialized in 2009. Its primary physical characteristics include a (1) beam energy of 50 kV, (2) dose rate of 20 Gy/min (computer controlled), (3) tube/applicator diameter of 2.5 cm, (4) real-time image control of the tumor during treatment (by fiberoscopy), (5) source-to-skin (mucosal) distance of 2–5 cm, and (6) surface treatment area of 3–12 cm². The use of Papillon 50® machine will be performed within the frame of the CONTEM trial in three clinical situations: (1) preoperative CXRT after local excision for pT1N0 disease, (2) neoadjuvant treatment of T2N0 not exceeding 4 cm (using CXRT with EBRT and concurrent chemotherapy followed by local excision following good tumor response), and (3) inoperable elderly patients treated with curative intent for T2–3 N0(1) with various combinations of CXRT and EBRT ± chemotherapy, brachytherapy, or local excision.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lamarque PL, Gros CG. La radiothérapie de contact des cancers du rectum. J Radiol Electrol. 1946;27:333–348.
Papillon J. Rectal and anal cancer. Conservative treatment by irradiation: an alternative to radical surgery. Berlin: Springer; 1982.
Papillon J. Present status of radiation therapy in the conservative management of rectal cancer. Radiother Oncol. 1990;17(4):275–283.
Gérard JP, Ayzac L, Coquard R, et al. Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon technique. Int J Radiat Oncol Biol Phys. 1996;36:775–783.
Maingon P, Guerif S, Darsouni R, et al. Conservative management of rectal adenocarcinoma by radiotherapy. Int J Radiat Oncol Biol Phys. 1998;40(5):1077–1085.
Rauch P, Bey P, Peiffet D, Conroy T, Bresler L. Factors affecting local control and survival after treatment of carcinoma of the rectum by endocavitary radiation. Int J Radiat Oncol Biol Phys. 2001;49:117–124.
Aumock A, Birnbaum EH, Fleshman JW, et al. Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumors. Int J Radiat Oncol Biol Phys. 2001;51(2):363–370.
Sischy B, Graney MJ, Hinson EJ. Endocavitary irradiation for adenocarcinoma of the rectum. CA Cancer J Clin. 1984;34(6):333–339.
Mendenhall WM, Rout WR, Vauthey JN, Haigh LS, Zlotecki RA, Copeland EM. Conservative treatment of rectal adenocarcinoma with endocavitary irradiation or wide local excision and postoperative irradiation. J Clin Oncol. 1997;15(10):3241–3248.
Sun Myint A, Grieve RJ, McDonald AC, et al. Combined modality treatment of early rectal cancer: the UK experience. Clin Oncol (R Coll Radiol). 2007;19(9):674–681.
Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2–T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54(1):142–149.
Gerard JP, Chapet O, Romestaing P, Favrel V, Barbet N, Mornex F. Local excision and adjuvant radiotherapy for rectal adenocarcinoma T1-2 N0. Gastroenterol Clin Biol. 2000;24(4):430–435.
Myerson RJ, Hunt SR. Conservative alternative to extirpative surgery for rectal cancer. Clin Oncol. 2007;19:682–686.
Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol. 2004;22(12):2404–2409.
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative radiochemotherapy for rectal cancer. N Engl J Med. 2004;351(17):7131–7140.
Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–1123.
Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–1644.
Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.
Gérard JP, Ortholan C, Benezery K, et al. Contact X-ray therapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice, 2002–2006. Int J Radiat Oncol Biol Phys. 2008;72(3):665–670.
Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc. 2008;22(2):352–358.
Kim CJ, Yeatman TJ, Coppola D, et al. Local excision of T2 and T3 rectal cancers after down staging chemoradiation. Ann Surg. 2001;34:352–358.
Ruo L, Guillem JG, Minsky BD, et al. Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers. Int J Colorectal Dis. 2002;17:54–58.
Bonnen M, Crane C, Vouthey JN, et al. Long-term results using Local excision after preoperating chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys. 2004;60:1098–1105.
Lindegaard J, Gerard JP, Sun Myint A, Myerson R, Thomsen H, Laurberg S. Whither papillon? Future directions for contact radiotherapy in rectal cancer. Clin Oncol (R Coll Radiol). 2007;19(9):738–741.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press
About this chapter
Cite this chapter
Gérard, JP., Myerson, R., Myint, A.S. (2010). Contact X-Ray Therapy. In: Czito, B., Willett, C. (eds) Rectal Cancer. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-567-5_16
Download citation
DOI: https://doi.org/10.1007/978-1-60761-567-5_16
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-566-8
Online ISBN: 978-1-60761-567-5
eBook Packages: MedicineMedicine (R0)